SELLAS Life Sciences Beats Q1 Earnings Expectations

The biopharmaceutical company exceeded analyst forecasts for its first quarter financial results.

Mar. 21, 2026 at 11:54am

Got story updates? Submit your updates here. ›

SELLAS Life Sciences Group (NASDAQ:SLS), a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, reported its first quarter 2026 earnings results. The company posted a loss of $0.05 per share, beating the analyst consensus estimate of a $0.06 per share loss.

Why it matters

SELLAS Life Sciences' positive earnings surprise demonstrates progress in the development of its lead product candidate, galinpepimut-S, an investigational multi-peptide vaccine targeting the Wilms' tumor 1 (WT1) antigen. Beating expectations could help boost investor confidence in the company's pipeline and future growth prospects.

The details

For the first quarter, SELLAS reported a net loss of $0.05 per share, exceeding the average analyst estimate of a $0.06 per share loss. The company's shares opened at $4.76 on Friday, up from a 52-week low of $0.95 and a high of $6.14. SELLAS has a market capitalization of $678.02 million and a beta of 2.18.

  • SELLAS Life Sciences Group reported its Q1 2026 earnings results on Thursday, March 21, 2026.

The players

SELLAS Life Sciences Group

A clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, headquartered in Waltham, Massachusetts.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

SELLAS Life Sciences' positive earnings surprise demonstrates progress in the development of its lead cancer immunotherapy product, which could help boost investor confidence in the company's future growth prospects.